Weixiao Dai

Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials

Jessica Howard‐Anderson, Toshimitsu Hamasaki, Weixiao Dai et al. · Clinical Infectious Diseases · 2022 · 33 citations · Full text

Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial

Ephraim L. Tsalik, Nadine Rouphael, Ruxana T. Sadikot et al. · The Lancet Infectious Diseases · 2022 · 25 citations · Full text

Antibiotics, Low Procalcitonin, Respiratory Infection +6

Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Jessica Howard‐Anderson, Toshimitsu Hamasaki, Weixiao Dai et al. · Clinical Infectious Diseases · 2023 · 16 citations · Full text

A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection

Jessica Howard‐Anderson, Weixiao Dai, Dafna Yahav et al. · Open Forum Infectious Diseases · 2022 · 15 citations · Full text

The Data and Safety Monitoring Board: The Toughest Job in Clinical Trials

Scott Evans, Lijuan Zeng, Weixiao Dai · NEJM Evidence · 2023 · 15 citations